Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Sep;18(3):393–400. doi: 10.1111/j.1365-2125.1984.tb02481.x

The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics.

T K Daneshmend, C J Roberts
PMCID: PMC1463662  PMID: 6487478

Abstract

The oral and intravenous pharmacokinetics of labetalol were determined in five subjects before and after a 3 week course of glutethimide 500 mg/day. After glutethimide there was a significant reduction in the AUC after the oral dose of labetalol, from 40,596 +/- 11,534 (mean +/- s.e. mean) to 22,057 +/- 6,276 ng ml-1 min (2P less than 0.05), and systemic bioavailability was reduced from 30.3 +/- 2.8 to 17.0 +/- 3.5% (2P less than 0.001). There was no significant change in labetalol plasma concentration-time curve (AUC) following an intravenous dose, half-life, volume of distribution, and plasma clearance. The oral and intravenous pharmacokinetics of labetalol were determined in six subjects before and after a 3 day course of cimetidine 1.6 g/day. After cimetidine there was a significant reduction in the volume of distribution of labetalol, from 520 +/- 51 to 445 +/- 24 1 (2P less than 0.05). The AUC of labetalol after the oral dose increased by 66%, from 51,029 +/- 7,950 to 84,772 +/- 19,444 ng ml-1 min (2P = 0.06). The systemic bioavailability of labetalol increased from 25.1 +/- 2.4 to 39.0 +/- 7.6% (2P = 0.06). There was no significant change in labetalol AUC after the intravenous dose, half life, and plasma clearance. There were no significant changes in resting heart rate and supine systolic and diastolic blood pressure following labetalol plus glutethimide, or labetalol plus cimetidine.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
393

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Branch R. A., Shand D. G., Wilkinson G. R., Nies A. S. Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow. J Clin Invest. 1974 Apr;53(4):1101–1107. doi: 10.1172/JCI107647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Daneshmend T. K., Ene M. D., Parker G., Roberts C. J. Effects of chronic oral cimetidine on apparent liver blood flow and hepatic microsomal enzyme activity in man. Gut. 1984 Feb;25(2):125–128. doi: 10.1136/gut.25.2.125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Feely J., Wilkinson G. R., Wood A. J. Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med. 1981 Mar 19;304(12):692–695. doi: 10.1056/NEJM198103193041202. [DOI] [PubMed] [Google Scholar]
  4. Fine A., Churchill D. N. Potentially lethal interaction of cimetidine and morphine. Can Med Assoc J. 1981 Jun 1;124(11):1434–1436. [PMC free article] [PubMed] [Google Scholar]
  5. Heagerty A. M., Donovan M. A., Castleden C. M., Pohl J. F., Patel L., Hedges A. Influence of cimetidine on pharmacokinetics of propranolol. Br Med J (Clin Res Ed) 1981 Jun 13;282(6280):1917–1919. doi: 10.1136/bmj.282.6280.1917. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Homeida M., Jackson L., Roberts C. J. Decreased first-pass metabolism of labetalol in chronic liver disease. Br Med J. 1978 Oct 14;2(6144):1048–1050. doi: 10.1136/bmj.2.6144.1048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Klotz U., Reimann I. Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam. Eur J Clin Pharmacol. 1980 Nov;18(6):517–520. doi: 10.1007/BF00874666. [DOI] [PubMed] [Google Scholar]
  8. Mojaverian P., Swanson B. N., Vlasses P. H., Ferguson R. K. Potentially lethal interaction of cimetidine and morphine. Can Med Assoc J. 1981 Dec 1;125(11):1212–1213. [PMC free article] [PubMed] [Google Scholar]
  9. Ohnhaus E. E., Thorgeirsson S. S., Davies D. S., Breckenridge A. Changes in liver blood flow during enzyme induction. Biochem Pharmacol. 1971 Oct;20(10):2561–2570. doi: 10.1016/0006-2952(71)90164-x. [DOI] [PubMed] [Google Scholar]
  10. Patwardhan R. V., Johnson R. F., Hoyumpa A., Jr, Sheehan J. J., Desmond P. V., Wilkinson G. R., Branch R. A., Schenker S. Normal metabolism of morphine in cirrhosis. Gastroenterology. 1981 Dec;81(6):1006–1011. [PubMed] [Google Scholar]
  11. Perucca E., Hedges A., Makki K. A., Richens A. A comparative study of antipyrine and lignocaine disposition in normal subjects and in patients treated with enzyme-inducing drugs. Br J Clin Pharmacol. 1980 Nov;10(5):491–497. doi: 10.1111/j.1365-2125.1980.tb01794.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Perucca E., Richens A. Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. Br J Clin Pharmacol. 1979 Feb;7(2):201–206. doi: 10.1111/j.1365-2125.1979.tb00922.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Perucca E., Richens A. Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients. Br J Clin Pharmacol. 1979 Jul;8(1):21–31. doi: 10.1111/j.1365-2125.1979.tb05904.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Puurunen J., Pelkonen O. Cimetidine inhibits microsomal drug metabolism in the rat. Eur J Pharmacol. 1979 May 1;55(3):335–336. doi: 10.1016/0014-2999(79)90205-x. [DOI] [PubMed] [Google Scholar]
  15. Roberts C. J., Jackson L., Halliwell M., Branch R. A. The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man. Br J Clin Pharmacol. 1976 Oct;3(5):907–913. doi: 10.1111/j.1365-2125.1976.tb00646.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rowland M., Benet L. Z., Graham G. G. Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm. 1973 Apr;1(2):123–136. doi: 10.1007/BF01059626. [DOI] [PubMed] [Google Scholar]
  17. Wilkinson G. R., Shand D. G. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975 Oct;18(4):377–390. doi: 10.1002/cpt1975184377. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES